We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.10 | 0.10% | 97.60 | 619 | 12:47:03 |
By Cecilia Butini
Novartis AG said it has suspended production of two of its oncology drugs at sites in Italy and New Jersey, U.S., as a result of potential quality issues in the manufacturing process.
The halt affects manufacture of gastroenteropancreatic neuroendocrine tumor drug Lutathera and of prostate-cancer drug Pluvicto, Novartis said, adding that the action affects commercial and clinical-trial supply.
The Swiss pharma major expects to resolve the issues and resume some supply within six weeks, pending confirmation via a continuing review, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
May 05, 2022 11:59 ET (15:59 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions